A New Matrix for Soft Tissue Management

Area of Science:

• Periodontology
• Regenerative Dentistry
• Mucogingival Surgery

Background:

• Gingival recession, an apical shift of the gingival margin from the cement-enamel junction (CEJ), is a common mucogingival defect.
• Connective tissue grafts (CTG) provide excellent results for treating gingival recession but have associated disadvantages.
• Xenogeneic collagen matrix (XCM) presents an alternative material for root coverage procedures.

Purpose of the Study:

• To systematically review the literature and perform a meta-analysis on the clinical efficacy of xenogeneic collagen matrix (XCM) for treating gingival recessions.
• To compare the outcomes of XCM with connective tissue grafts (CTG) and alone in root coverage procedures.

Main Methods:

• Systematic literature review conducted following Cochrane Handbook guidelines.
• Meta-analysis performed to calculate relative risks and standardized mean differences for clinical variables.
• Comparison of outcomes for connective flap surgery + connective tissue graft (CAF + CTG) versus connective flap surgery + xenogeneic collagen matrix (CAF + XCM) and connective flap surgery alone (CAF).

Main Results:

• CAF + CTG demonstrated statistically significant superiority over CAF + XCM in complete root coverage, mean root coverage, recession reduction, clinical attachment level, and gingival thickness.
• CAF + XCM showed slight advantages over CAF alone in mean root coverage, recession reduction, and gingival thickness.
• Specific relative risk (RR) and standardized mean difference (SMD) values were reported for each variable, indicating the magnitude of differences.

Conclusions:

• Connective tissue grafts (CTG), when used with connective flap surgery (CAF + CTG), remain the gold standard for achieving root coverage.
• Xenogeneic collagen matrix (XCM) offers some benefits compared to no grafting material but is less effective than CTG for root coverage procedures.
• Further research may be needed to optimize the use of XCM or identify specific indications where it could be a viable alternative.